A detailed history of China Universal Asset Management Co., Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 12,183 shares of BPMC stock, worth $1.12 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
12,183
Previous 7,355 65.64%
Holding current value
$1.12 Million
Previous $792,000 42.17%
% of portfolio
0.13%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$84.1 - $120.5 $406,034 - $581,774
4,828 Added 65.64%
12,183 $1.13 Million
Q2 2024

Jul 19, 2024

SELL
$85.18 - $108.78 $376,665 - $481,025
-4,422 Reduced 37.55%
7,355 $792,000
Q1 2024

Apr 29, 2024

BUY
$73.17 - $99.79 $347,191 - $473,503
4,745 Added 67.48%
11,777 $1.12 Million
Q4 2023

May 21, 2024

SELL
$43.96 - $92.84 $208,590 - $440,525
-4,745 Reduced 40.29%
7,032 $648,000
Q4 2023

Jan 23, 2024

BUY
$43.96 - $92.84 $240,988 - $508,948
5,482 Added 353.68%
7,032 $649,000
Q3 2023

May 21, 2024

BUY
$46.9 - $66.0 $35,503 - $49,962
757 Added 95.46%
1,550 $77,000
Q3 2023

Oct 30, 2023

BUY
$46.9 - $66.0 $35,503 - $49,962
757 Added 95.46%
1,550 $78,000
Q2 2023

May 21, 2024

SELL
$42.2 - $66.37 $844 - $1,327
-20 Reduced 2.46%
793 $50,000
Q2 2023

Jul 27, 2023

SELL
$42.2 - $66.37 $844 - $1,327
-20 Reduced 2.46%
793 $50,000
Q1 2023

May 21, 2024

BUY
$37.97 - $50.0 $7,783 - $10,250
205 Added 33.72%
813 $36,000
Q1 2023

Apr 27, 2023

BUY
$37.97 - $50.0 $7,783 - $10,250
205 Added 33.72%
813 $37,000
Q4 2022

May 21, 2024

SELL
$41.06 - $66.48 $458,599 - $742,515
-11,169 Reduced 94.84%
608 $26,000
Q4 2022

Jan 31, 2023

BUY
$41.06 - $66.48 $2,011 - $3,257
49 Added 8.77%
608 $27,000
Q3 2022

Oct 21, 2022

BUY
$49.93 - $77.7 $27,910 - $43,434
559 New
559 $37,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.47B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.